NCT06372821招募中1 期
A Randomized, Participant & Investigator Blinded, Placebo-Controlled Study to Evaluate the Ability of Intrathecally Administered NIO752 to Lower CSF Total Tau Synthesis in Participants With AD Measured by Stable Isotope Labelling Kinetics
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Tau synthesis rate inhibition in individuals with sporadic AD and ADAD
研究概览
简要总结
This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage. Abnormal tau proteins cling to each other forming 'tangles' inside nerve cells, which interfere with how the nerve cells work, and eventually die. This is what causes the symptoms of dementia. It is thought that NIO752 reduces production of tau.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 21 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to provide signed informed consent.
- •Between 21 to 80 years old (inclusive).
- •A diagnosis of mild or moderate Alzheimer's disease by a Clinical Dementia Rating score of 0.5 to 2, where the investigator believes they will be able to complete the study.
- •A history of cerebrospinal fluid, Positron Emission Topography (PET), or blood-based biomarkers supporting the diagnosis of Alzheimer's disease, or symptomatic approved presenilin (PSEN) or amyloid precursor protein (APP) mutation carriers. If blood biomarkers are equivocal then amyloid status can be confirmed using cerebrospinal fluid.
- •Fluency in English
- •Participant has a reliable study partner or caregiver
- •Able to undergo lumbar punctures, magnetic resonance imaging (MRI), cerebrospinal fluid draws, and blood draws.
- •Individuals will be willing to consent for their biological samples and personal data to be shared with the commercial partner (Novartis)
排除标准
- •Live in a skilled nursing facility or dementia care facility.
- •Any clinically significant laboratory abnormality
- •Attempted suicide, suicidal ideation with a plan that required hospital admission within 12 months prior to Screening
- •Any previous use of experimental therapy within 180 days or 5 half-lives prior to Day 1, whichever is greater.
- •Any previous use of MAPT antisense oligonucleotides (ASO) or any other ASO or other gene therapy meant as treatment for Alzheimer's disease.
- •History of hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical classes.
- •Any condition that increases risk of meningitis unless participant is receiving appropriate prophylactic treatment.
- •Current medical or non-Alzheimer's disease neurological condition that might impact cognition or performance on cognitive assessments
- •Have any other conditions which, in the opinion of the investigator, would make the participant unsuitable for inclusion or could interfere with the patient participating in or completing the study.
- •Unlikely to cooperate in the study; not able to attend scheduled examinations and visits; or not able to follow study instructions per the judgement of the investigator.
- •Current alcohol (>14 units per week) or current cannabis use; or history of alcohol or drug abuse or dependence (except nicotine dependence) within 2-years before the screening visit.
- •Treatment with immunosuppressants, antipsychotics, lithium, neuroleptics, dopaminergic agonists, L-dopa, or monoamine oxidase inhibitors at the time of screening. Current use of medications, other than cholinesterase inhibitors and/or memantine, that could alter cognition, as determined by the Investigator. If patients are taking cholinesterase inhibitors and/or memantine at screening, the dose must have been stable within 12-weeks prior to screening and must remain stable during the duration of the study.
- •Unable to undergo MRI due to for example claustrophobia, or presents absolute contraindications to MRI (e.g., metallic implants, metallic foreign bodies, pacemaker, defibrillator).
- •Significant signs of major cerebrovascular disease
- •Sexually active males, unless they agree to use a condom during intercourse from the time of consent until a minimum of 15 weeks after treatment.
- •Breast feeding women, pregnant women, and females of reproductive potential unless they use highly effective contraception methods, as specified in the protocol.
- •Patients on regular anticoagulants or anti-platelets that would preclude lumbar puncture are not eligible to participate
- •Seropositive for human immunodeficiency virus (HIV), Hepatitis B or hepatitis C.
研究组 & 干预措施
NIO752
Experimental
Intrathecal administration.
干预措施: NIO752 (Drug)
Saline
Placebo Comparator
10mL of saline (placebo) is administered intrathecally.
干预措施: NIO752 (Drug)
Saline
Placebo Comparator
10mL of saline (placebo) is administered intrathecally.
干预措施: Placebo (Other)
结局指标
主要结局
Tau synthesis rate inhibition in individuals with sporadic AD and ADAD
时间窗: Day 23
Tau synthesis rate calculated using tracer to tracee ratio of tau specific peptide calculated on day 20 post leucine administration in individuals with sporadic and ADAD (analyzed collectively) receiving intrathecal NIO752 compared to placebo.
次要结局
- Compare efficacy of knockdown of tau production in sporadic AD and ADAD by measuring the synthesis rate of tau by determining the ratio of labelled to unlabeled tau (tracer to tracee ratio) in serial cerebrospinal fluid samples.(Day 23)
- Number of participants with adverse events [safety and tolerability](Day 0 to Day 145)
- Comparison of number of Adverse Events reported between participants receiving one dose of NIO752 versus those receiving two doses of NIO752.(Day 0 to Day 145)
- Determine CSF tau concentration to tau production relationships in humans(120 days)
- Compare rates of tau synthesis and clearance in sporadic AD and ADAD(Day 23)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke PatientsCerebrovascular AccidentNCT00044070Astellas Pharma Inc
已完成
1 期
A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy SubjectsHealthy VolunteerNCT01365338Biogen112
已完成
不适用
Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in AgingHealthy Elderly VolunteersNCT03818802Mayo Clinic53
终止
1 期
Study to Learn More About the Effect of a New Drug Called BAY2327949 on the Blood Flow Through Kidneys in Adult Participants With Moderate Chronic Kidney DiseaseModerate Chronic Kidney DiseaseNCT04552262Bayer7
终止
1 期
Dose Response Relationship of Oxytocin on Irritability in YouthsIrritable MoodNCT03863288University of Nebraska60